Rachel Caspar, MD
Addiction Medicine · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Caspar’s office at (916) 443-3299 to ask if they take your plan before you enroll.
California Medical Board record
Licence A168974 · Current
Licensed to practise in California · since 2020 · expires 2028-06-30 · University of Arizona College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
- American Board of Preventive Medicine - Addiction Medicine
Medicaid work
$321,924 in 2023
Medicaid paid $321,924 for 3,261 billed services this clinician did in 2023, up to 107 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,110 | $317,586 |
| Short return visit (20+ min) | 1,526 | $3,780 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 447 | $323 |
| Return visit (30+ min) | 178 | $235 |
| 2023 | 3,261 | 4 | 107 | $321,924 |
| 2022 | 3,473 | 5 | 105 | $317,407 |
| 2021 | 5,046 | 5 | 143 | $467,514 |
| 2020 | 1,564 | 3 | 141 | $135,662 |
See the largest Medicaid services in earlier years
2022
| Clinic visit/encounter, all-inclusive | 1,162 | $314,249 |
| Short return visit (20+ min) | 1,631 | $2,081 |
| Return visit (30+ min) | 340 | $918 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 313 | $121 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 27 | $38 |
2021
| Clinic visit/encounter, all-inclusive | 1,961 | $466,258 |
| Short return visit (20+ min) | 2,188 | $897 |
| Return visit (30+ min) | 794 | $338 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 86 | $22 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 17 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 592 | $135,353 |
| Short return visit (20+ min) | 758 | $310 |
| Return visit (30+ min) | 214 | $0 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their 800 Part D prescriptions in 2021.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 288 | 40 | None | None | $61,828 |
| 2022 | 437 | 69 | None | None | $88,886 |
| 2021 | 800 | 107 | 3% (22) | None | $97,253 |
| 2020 | 183 | 45 | None | 23% | $26,737 |
| 2019 | 192 | 33 | 0% (0) | 15% | $11,732 |
| 2018 | 235 | 53 | None | 21% | $60,194 |
| 2017 | 13 | None | 0% (0) | None | $352 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Vivitrol | 22 | $27,597 | $1,254 |
| Buprenorphine-Naloxone | 79 | $15,625 | $198 |
| Suboxone | 12 | $8,560 | $713 |
| Buprenorphine | 48 | $2,603 | $54 |
| Omeprazole | 11 | $246 | $22 |
2022: 8 drugs
| Vivitrol | 20 | $30,747 | $1,537 |
| Buprenorphine-Naloxone | 110 | $21,914 | $199 |
| Suboxone | 26 | $11,028 | $424 |
| Buprenorphine | 53 | $4,793 | $90 |
| Gabapentin | 19 | $412 | $22 |
| Tamsulosin | 13 | $160 | $12 |
| Omeprazole | 20 | $158 | $8 |
| Trazodone | 12 | $59 | $5 |
2021: 20 drugs
| Buprenorphine-Naloxone | 199 | $33,380 | $168 |
| Suboxone | 32 | $13,826 | $432 |
| Vivitrol | 11 | $13,672 | $1,243 |
| Buprenorphine | 44 | $3,158 | $72 |
| Narcan | 22 | $2,828 | $129 |
| Albuterol Sulfate Hfa | 20 | $1,638 | $82 |
| Gabapentin | 33 | $542 | $16 |
| Ibuprofen | 28 | $298 | $11 |
| Sumatriptan | 16 | $246 | $15 |
| Hydroxyzine | 13 | $243 | $19 |
| Duloxetine | 11 | $229 | $21 |
| Tamsulosin | 19 | $209 | $11 |
| Omeprazole | 26 | $186 | $7 |
| Atorvastatin | 13 | $170 | $13 |
| Buspirone | 11 | $125 | $11 |
| Trazodone | 17 | $102 | $6 |
| Losartan | 11 | $74 | $7 |
| Amlodipine Besylate | 11 | $72 | $7 |
| Metformin | 11 | $65 | $6 |
| Lisinopril | 12 | $50 | $4 |
2020: 3 drugs
| Buprenorphine-Naloxone | 56 | $9,265 | $165 |
| Suboxone | 14 | $3,575 | $255 |
| Buprenorphine | 11 | $1,348 | $123 |
2019: 5 drugs
| Advair Hfa | 12 | $4,660 | $388 |
| Omeprazole | 11 | $379 | $34 |
| Levothyroxine | 14 | $378 | $27 |
| Gabapentin | 11 | $254 | $23 |
| Lisinopril | 12 | $68 | $6 |
2018: 4 drugs
| Levothyroxine | 15 | $500 | $33 |
| Gabapentin | 11 | $292 | $27 |
| Atorvastatin | 12 | $185 | $15 |
| Lisinopril | 11 | $53 | $5 |
Money from drug and device companies
$150 in 2025
| 2025 | 1 | 2 | None | $150 |
| 2024 | 1 | 1 | None | $100 |
| 2023 | 3 | 4 | None | $77 |
| 2022 | 2 | 2 | None | $104 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Braeburn | Brixadi | $150 | 2 payments
|
See all 2 published payments
| Braeburn | Meals · 2025-03-31 | Brixadi | $25 |
| Braeburn | Meals · 2025-01-16 | Brixadi | $125 |
See earlier years (2024, 2023, 2022)
2024: $100
| Braeburn | Brixadi | $100 | 1 payment
|
2023: $77
| Indivior | Sublocade | $34 | 2 payments
|
| Alkermes | Vivitrol | $24 | 1 payment
|
| Braeburn | Brixadi | $20 | 1 payment
|
2022: $104
| Gilead Sciences | Descovy | $83 | 1 payment
|
| Indivior | Sublocade | $21 | 1 payment
|
Professional record
- NPI
- 1053774273
- Licence
- CA A168974, UT 10483123-1205California A168974: Current · expires 2028-06-30
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207QA0401X (207QA0401X); Family medicine (207Q00000X)
- Mailing address
- 1500 21st St, Sacramento, CA, 95811
- NPI first listed
- 2016-04-04
- NPI last updated
- 2021-03-12
- NPI record certified
- 2021-03-12
This is when the NPI record was last certified, not a medical board exam.